The common therapies for CRVO treatment are laser photocoagulation for peripheral ischemia, macular laser for ME (occasionally) and intravitreal injections of anti-VEGF and steroids, which are used to ...

Real-world, 12-month results demonstrated efficacy, safety and durability for faricimab as a treatment for retinal vein ...

While the current therapies are effective for treating branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), they are inadequate for long-term treatment in clinical practice, ...

– Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous trials – – If approved by the FDA, RVO would be Vabysmo’s third indication in addition ...

Aflibercept was a less cost-effective treatment for retinal vein occlusion (RVO) compared with bevacizumab, although visual acuity outcomes were similar. Visual acuity outcomes were similar between ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated ...

Why did a 38-year-old woman with neurofibromatosis type 1 (NF1) develop choroidal Yasunari nodules in both eyes? That's what Danish clinicians had to figure out when the patient presented for a ...